Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? [Yahoo! Finance]
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: Yahoo! Finance
The change represents 0.31% of Cormorant's reportable 13F assets under management. The post-trade stake totaled 3,192,521 shares worth $94.82 million. Rapport Therapeutics now comprises 6.54% of AUM, making it the fund's 4th-largest holding. These 10 stocks could mint the next wave of millionaires › Cormorant Asset Management, LP reported a buy of 251,600 additional shares of Rapport Therapeutics (NASDAQ:RAPP) , as disclosed in its November 14, 2025, SEC filing . The newly reported position stands at 3,192,521 shares, valued at $94.82 million at quarter-end. The trade increased the stake by approximately $61.38 million, accounting for 0.31% of Cormorant's $1.45 billion in reportable U.S. equity assets. Cormorant Asset Management, LP increased its holding in Rapport Therapeutics; post-trade, the position represents 6.54% of 13F AUM. Top holdings after the filing: NASDAQ:BBOT: $207,034,119 (14.3% of AUM) NASDAQ:ABVX: $165,555,000 (11.4% of AUM) NASDAQ:EYPT: $118,548,0
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics (NASDAQ:RAPP) was given a new $51.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RAPP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
RAPP
Earnings
- 11/6/25 - Beat
RAPP
Sec Filings
- 12/18/25 - Form 4
- 12/17/25 - Form 144
- 12/17/25 - Form 144
- RAPP's page on the SEC website